Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Antituberculosis treatment halves risk of uveitis recurrence

25 Apr 2018

In patients with latent tuberculosis (TB)-associated uveitis, treatment with an anti-TB drug cuts the risk of uveitis recurrence by half and delays the onset of first recurrence, as reported in a recent study.

Researchers looked at 199 eyes of 129 patients, of whom 89 patients (69 percent) received anti-TB treatment. Uveitis was managed using local and systemic anti-inflammatory and immunosuppressive therapy.

Data on clinical outcome, vision and treatment were gathered and analysed. Outcomes of interest included best corrected visual acuity (BCVA) and rate of disease recurrence.

Over the follow-up period, mean change in BCVA following treatment was 4.5±1.4 letters. No significant difference was observed between eyes of patients receiving anti-TB treatment and those who did not.

Uveitis recurrence occurred in 68 eyes (34.9 percent; 0.64±0.08 recurrences per year), with eyes of patients receiving anti-TB treatment less likely to develop a recurrence (29.5 percent vs 48.2 percent).

Specifically, anti-TB treatment reduced the odds of developing recurrence by more than half (odds ratio, 0.47; 95 percent CI, 0.29–0.77; p=0.003). Eyes of patients who received the treatment recurred at an estimated median of 120 months vs 51 months in eyes of those who were not treated with an anti-TB drug (p=0.005).

The present data provide positive evidence of the benefit of treating latent TB-related uveitis with an anti-TB drug in addition to appropriate local and systemic anti-inflammatory therapy, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.